As reported by Healthcare Global, the uk pharma company, AstraZeneca’s thyroid cancer drug has been approved by EU drug regulators.
The drug, called Vandetanib which is marketed under the brand name of Caprelsa will be used to treat medullary thyroid cancer tumours which have spread to other parts of the body and cannot be treated in surgical.
The EU drug regulators reviewed the Phase III clinical trial data which indicated that use of the drug reduced the risk of disease progressing by 54 per cent. The drug works by stopping the blood from lowing to tumours and thus inhibiting their growth.
Experts in the pharmaceutical industry believe that Vandetanib could be AstraZeneca’s block busting drug. Thomson Reuters Pharma have estimated that by 2016 sales of the drug will hit $112million.
Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharma jobs now.